Altimmune to Participate at Two Upcoming Investor Conferences
On May 29, 2024, Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. The company management will attend the Jefferies Global Healthcare Conference in New York on June 5, 2024, with a fireside chat at 2:00 p.m. ET. They will also attend the Goldman Sachs Global Healthcare Conference in Miami Beach on June 12, 2024, with a fireside chat at 9:20 a.m. ET. Both sessions will be webcast and accessible via the Events section of Altimmune's website.
- Altimmune's participation in high-profile conferences enhances visibility among investors.
- Scheduled fireside chats provide a platform for management to discuss the company's strategy and progress.
- Webcasting the sessions ensures broad accessibility for stakeholders.
- No new financial or clinical data was disclosed in the announcement, which might disappoint investors seeking updates.
- The announcement does not include any immediate financial impact or milestones, possibly limiting stock movement.
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
- Jefferies Global Healthcare Conference (New York, NY)
Wednesday, June 5, 2024
Fireside Chat at 2:00 p.m. Eastern Time - Goldman Sachs Global Healthcare Conference (Miami Beach, FL)
Wednesday, June 12, 2024
Fireside Chat at 9:20 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
![](https://ml.globenewswire.com/media/YzVmNDFlMDYtYjlhMS00MzgwLWFmYTItNjA3ZDhjYmRlZDEyLTEwMjIyNDk=/tiny/Altimmune-Inc.png)
FAQ
When will Altimmune participate in the Jefferies Global Healthcare Conference?
At what time will Altimmune's fireside chat occur during the Jefferies Global Healthcare Conference?
When is Altimmune scheduled to attend the Goldman Sachs Global Healthcare Conference?
What time is Altimmune's fireside chat at the Goldman Sachs Global Healthcare Conference?